Alto Neuroscience, Inc. ANRO
22.33 USD -0.37 (-1.63%)
Nov 4, 2026, 11:06 AM EST
22.35 Day range 23.65
10.62 52-week range 37.48
- YTD
- +25.45%
- 1 year
- +98.84%
Financial health
Altman Z-Score
13.97 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 2
Valuation
P/E -8.1×
FY 2021 5y median -15.3× FY 2025
P/S 0.0×
FY 2021 5y median 0.0× FY 2025
P/B 3.4×
FY 2021 5y median -7.8× FY 2025
P/FCF -9.9×
FY 2021 5y median -16.4× FY 2025
EV/EBITDA -5.7×
FY 2021 5y median -14.0× FY 2025
EV/Sales 0.0×
FY 2021 5y median 0.0× FY 2025
FCF Yield -10.1%
FY 2021 5y median -6.1% FY 2025
Profitability
Gross Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2021 5y median 0.0% FY 2025
ROE -41.8%
FY 2021 5y median 50.7% FY 2025
ROIC -38.2%
FY 2021 5y median -44.7% FY 2025
ROA -34.2%
FY 2021 5y median -34.6% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2021 FY 2025
Operating Income 3.3%
FY 2021 FY 2025
EPS (diluted) 12.4%
FY 2021 FY 2025
Free Cash Flow -4.6%
FY 2021 FY 2025
Financial Health
Current Ratio 15.7×
FY 2021 5y median 15.3× FY 2025
Quick Ratio 15.7×
FY 2021 5y median 15.3× FY 2025
Debt / Equity 0.0×
FY 2021 5y median -0.1× FY 2025
Net Debt / EBITDA 2.9×
FY 2021 5y median 2.1× FY 2025
Interest Coverage -26.9×
FY 2021 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2021 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2021 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31